Safety Evaluation of Penfluridol, a New Long-Acting Oral Antipsychotic Agent

1974 ◽  
Vol 14 (4) ◽  
pp. 202-209 ◽  
Author(s):  
K. Y. OTA ◽  
A. A. KURLAND ◽  
V. B. SLOTNICK
Keyword(s):  
Safety Evaluation ◽  
Antipsychotic Agent ◽  
Oral Antipsychotic ◽  
Long Acting

scholarly journals Aripiprazole Lauroxil, a Novel Injectable Long-Acting Antipsychotic Treatment for Adults with Schizophrenia: A Comprehensive Review

2021 ◽  
Vol 13 (3) ◽  
pp. 279-296
Author(s):  
Kunal Maini ◽  
Haley Gould ◽  
Jessica Hicks ◽  
Fatima Iqbal ◽  
James Patterson ◽  
...  
Keyword(s):  
Partial Agonist ◽  
Antipsychotic Agent ◽  
The United States ◽  
Mental Health Disorder ◽  
Oral Dosage ◽  
Antipsychotic Treatment ◽  
Comprehensive Review ◽  
Social Commitment ◽  
Hearing Voices ◽  
Long Acting

Purpose of Review. This is a comprehensive review of the literature regarding the use of Aripiprazole lauroxil for schizophrenia. This review presents the background, evidence, and indications for using aripiprazole lauroxil to treat schizophrenia in the context of current theories on the development of schizophrenia. Recent Findings. Schizophrenia is a chronic mental health disorder that currently affects approximately 3.3 million people in the United States. Its symptoms, which must be present for more than six months, are comprised of disorganized behavior and speech, a diminished capacity to comprehend reality, hearing voices unheard by others, seeing things unseen by others, delusions, decreased social commitment, and decreased motivation. The majority of these symptoms can be managed with antipsychotic medication. Aripiprazole lauroxil is a long-acting intramuscular injection that works as a combination of partial agonist activity at D2 and 5-HT1A receptors combined with antagonist activity at 5-HT2A receptors. It can be dosed as a 4-, 6-, or 8-week injection, depending on oral dosage. Aripiprazole lauroxil was FDA approved in October of 2015. Summary. Schizophrenia is a severe psychiatric disorder if left untreated. There are multiple medications to help treat schizophrenia. One antipsychotic agent, aripiprazole lauroxil, offers long duration injections that optimize and improve compliance. Known side effects include weight gain, akathisia, neuroleptic malignant syndrome, tardive dyskinesia, and orthostatic hypotension. Aripiprazole lauroxil is an FDA-approved drug that can be administered monthly, every six weeks, or every two months and has been shown to be both safe and effective.

Short-acting antipsychotics or long-acting injectables? A treatment comparison in patients with schizophrenia

2020 ◽  
Vol 25 (03) ◽  
pp. 170-178 ◽  
Author(s):  
Helena Thiem ◽  
Here Folkerts ◽  
Lukas Völkel
Keyword(s):  
Length Of Stay ◽  
Average Length ◽  
Psychiatric Institute ◽  
Real World Data ◽  
Short Acting ◽  
Treatment Comparison ◽  
Average Length Of Stay ◽  
Before And After ◽  
Oral Antipsychotic ◽  
Long Acting

Abstract Aim This research aims to compare the efficacy and direct costs of short-acting oral antipsychotics and aripiprazole once-monthly (AOM) in the context of the treatment of patients with schizophrenia based on real-world data in Germany. Method Results are based on a single-armed, retrospective, non-interventional pre-post comparison study evaluating data from 132 patients with schizophrenia before and after switching from oral antipsychotics to AOM treatment (6 months each). Socio-demographics, as well as parameters of indication, efficacy and resource consumption were analyzed and statistically evaluated. Results The switch from an oral antipsychotic medication to AOM led to a distinct improvement in all clinically relevant parameters, including a reduction in hospitalization rates (55.1 % vs. 14.0 %), length of stay (43.5 d vs. 34.8 d) and percentage of patients with multiple hospitalizations (13.6 % vs. 3.8 %). There was also a reduction in schizophrenic episodes for patients with ≥ 1 episode (2.9 vs. 1.4) and of the percentage of patients with ≥ 1 (88.0 % vs. 29.3 %) as well as ≥ 2 (60.0 % vs. 8.1 %) schizophrenic episodes. The proportion of patients requiring a visit to day clinics or psychiatric institute outpatient clinics (PIA) decreased (39.5 % vs. 8.4 %) for patients with AOM treatment, as did the average length of stay in day clinics or PIAs (116.8 d vs. 86.4 d) for patients with ≥ 1 stay. The cost saving potential of AOM compared to the treatment with oral antipsychotics ranged between 1,729.32 € and 5,048.53 € per patient for a six-month observation period. Conclusion Our results suggest that AOM treatment of patients with schizophrenia is more effective (reduction in schizophrenic episodes, hospitalizations, stays in day clinics, psychiatrist visits, losses in productivity) and generates lower costs for the statutory health insurance (SHI) in Germany than treatment with oral antipsychotics and should therefore not be regarded as only a last-resort treatment option for schizophrenia.

scholarly journals T236. A PROGRAM TO INCREASE THE APPROPRIATE USE OF LONG-ACTING ANTIPSYCHOTIC MEDICATIONS IN COMMUNITY SETTINGS

2020 ◽  
Vol 46 (Supplement_1) ◽  
pp. S322-S323
Author(s):  
Dawn Velligan ◽  
Martha Sajatovic
Keyword(s):  
Decision Making ◽  
Shared Decision Making ◽  
Antipsychotic Medication ◽  
Poor Adherence ◽  
Shared Decision ◽  
Appropriate Use ◽  
Antipsychotic Medications ◽  
Oral Antipsychotic ◽  
Long Acting ◽  
Over Time

Abstract Background Antipsychotic medications are evidence-based treatments for schizophrenia that improve health outcomes and reduce costs. However, rates of non-adherence to oral antipsychotic medications can exceed 60%. We examined whether a simple checklist to identify individuals not receiving optimum benefit from current oral antipsychotic treatment (NOB Checklist) and The Multi-level Facilitation of Long-acting Antipsychotic Medication Program (MAP) could increase the appropriate use of long-acting injectable antipsychotic medication (LAI) in community clinics. Methods Two clinics in Texas and two in Ohio changed clinical procedures in one of two ways 1) NOB only clinics--providers used a five-item checklist to identify individuals with schizophrenia on oral antipsychotics who were Not receiving Optimum Benefit from current treatment and may therefore benefit from a switch to LAI. 2) MAP- providers used the NOB checklist AND received MAP; MAP is a novel behavior change intervention designed to improve the identification of individuals who could benefit from LAI, improve their outcomes and reduce inappropriate use of resources associated with poor adherence. MAP targets 3 stakeholder groups 1) the consumer for whom peer specialists showed a video describing shared decision making and how to make a choice between tablets and injections, and provided a balanced shared-decision making tool to assist them in choosing medication route,2) the provider who received academic detailing describing various LAI options, how to make good offers as part of a shared decision making dialogue, and important benefits of LAI including the ability to disentangle efficacy versus poor adherence and to help individuals with cognitive and practical problems that lead to poor adherence, and 3) the administrators who received information on how LAI could improve outcomes for individuals and clinic processes, how to encourage the use of LAI among providers and how to provide regular feedback to providers about prescribing practices. The primary outcome was the percentage of LAI versus oral antipsychotic medication prescribed to individuals with schizophrenia. Results Higher NOB checklist scores were associated with an increased provider likelihood of LAI offers and increased consumer acceptance of LAI. All clinics increased use of LAI over time. In Texas, where MAP was fully implemented, the MAP clinic had greater use of LAI over time (eventually reaching about 50% of all antipsychotic use) vs. the NOB only clinic. In Cleveland, the patient stakeholder curriculum was not delivered and there was no significant difference in LAI use between MAP and NOB clinics. Discussion The NOB checklist appears to be a useful tool to help identify patients who might be appropriate candidates for LAI and the full MAP program may help clinicians and consumers to work together to optimize the appropriate use of LAI in outpatient settings. Implementation must be customized for clinics and workflows to determine which parts of the MAP program are practical and appropriate. Participation of consumer stakeholders may be essential to delivery of the MAP Program.

scholarly journals Antipsychotic long-acting injections: Prescribing practice in the UK

2009 ◽  
Vol 195 (S52) ◽  
pp. s37-s42 ◽  
Author(s):  
Thomas R. E. Barnes ◽  
Amber Shingleton-Smith ◽  
Carol Paton
Keyword(s):  
Demographic Variables ◽  
High Dose ◽  
Clinical Settings ◽  
Audit Data ◽  
Younger Age ◽  
Prescribing Practice ◽  
The Usa ◽  
Oral Antipsychotic ◽  
Long Acting ◽  
The Uk

BackgroundData from the USA, Australia and Europe suggest that the proportion of patients with schizophrenia prescribed an antipsychotic long-acting injection (LAI) varies from around a quarter to a third. Use of LAIs has been associated with male gender and younger age.AimsTo characterise the use of LAIs in people with schizophrenia in three clinical settings in the UK.MethodThe study used audit data from quality improvement programmes conducted by the Prescribing Observatory for Mental Health.ResultsLong-acting injections were found to be prescribed for between a quarter and a third of patients, depending on the clinical setting. Flupentixol, risperidone and zuclopenthixol were most commonly prescribed and were combined with an oral antipsychotic in half of cases, frequently constituting high-dose prescribing. The use of LAIs was not consistently associated with age, gender or ethnicity.ConclusionsAntipsychotic LAIs are commonly prescribed. We did not replicate previous findings with respect to demographic variables associated with their use.

scholarly journals Treatment patterns in Medicaid patients with schizophrenia initiated on a first- or second-generation long-acting injectable versus oral antipsychotic

2017 ◽  
Vol Volume 11 ◽  
pp. 619-629 ◽  
Author(s):  
Dominic Pilon ◽  
Kruti Joshi ◽  
Neeta Tandon ◽  
Marie-Hélène Lafeuille ◽  
Rhiannon Kamstra ◽  
...  
Keyword(s):  
Second Generation ◽  
Treatment Patterns ◽  
Oral Antipsychotic ◽  
Long Acting
Sign in / Sign up

Export Citation Format

Share Document